Asia Pacific Pediatric Cancer Biomarker Market Size & Outlook
The pediatric cancer biomarker market in Asia Pacific is expected to reach a projected revenue of US$ 348.4 million by 2030. A compound annual growth rate of 10.2% is expected of Asia Pacific pediatric cancer biomarker market from 2024 to 2030.
Revenue, 2023 (US$M)
$177.1
Forecast, 2030 (US$M)
$348.4
CAGR, 2024 - 2030
10.1%
Report Coverage
Asia Pacific
Asia Pacific pediatric cancer biomarker market, 2018-2030 (US$M)
Asia Pacific pediatric cancer biomarker market highlights
- The Asia Pacific pediatric cancer biomarker market generated a revenue of USD 177.1 million in 2023.
- The market is expected to grow at a CAGR of 10.2% from 2024 to 2030.
- In terms of segment, leukemia was the largest revenue generating indication in 2023.
- Leukemia is the most lucrative indication segment registering the fastest growth during the forecast period.
Asia Pacific data book summary
| Market revenue in 2023 | USD 177.1 million |
| Market revenue in 2030 | USD 348.4 million |
| Growth rate | 10.2% (CAGR from 2023 to 2030) |
| Largest segment | Leukemia |
| Fastest growing segment | Leukemia |
| Historical data covered | 2018 - 2022 |
| Base year for estimation | 2023 |
| Forecast period covered | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Leukemia |
Other key industry trends
- In terms of revenue, Asia Pacific region accounted for 21.7% of the global pediatric cancer biomarker market in 2023.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 348.4 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Pediatric Cancer Biomarker Market Scope
Pediatric cancer biomarker market segmentation & scope
Biomarker
Alpha - fetoprotein (AFP)
Neuron - specific enolase (NSE)
CD19, CD20, CD22
ALK (anaplastic lymphoma receptor tyrosine kinase gene)
Others
End Use
Hospital
Diagnostic Laboratories
Oncology Centers
Research Institutions
Countries
Canada
Mexico
U.S.
Denmark
France
Germany
Italy
Norway
Spain
Sweden
UK
Australia
China
India
Japan
South Korea
Thailand
Argentina
Brazil
Kuwait
Saudi Arabia
South Africa
UAE
Pediatric Cancer Biomarker Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Asia Pacific pediatric cancer biomarker market
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
